GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » Shiller PE Ratio

EBS (Emergent BioSolutions) Shiller PE Ratio : (As of Jun. 29, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Emergent BioSolutions Shiller PE Ratio Historical Data

The historical data trend for Emergent BioSolutions's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Shiller PE Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.45 21.77 7.51 140.14 -

Emergent BioSolutions Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.61 - - - -

Competitive Comparison of Emergent BioSolutions's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Shiller PE Ratio falls into.


;
;

Emergent BioSolutions Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Emergent BioSolutions's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Emergent BioSolutions's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.19/134.9266*134.9266
=1.190

Current CPI (Mar. 2025) = 134.9266.

Emergent BioSolutions Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 0.320 100.684 0.429
201509 0.790 100.392 1.062
201512 0.710 99.792 0.960
201603 0.100 100.470 0.134
201606 -0.270 101.688 -0.358
201609 0.450 101.861 0.596
201612 0.670 101.863 0.887
201703 0.230 102.862 0.302
201706 0.110 103.349 0.144
201709 0.680 104.136 0.881
201712 0.670 104.011 0.869
201803 -0.100 105.290 -0.128
201806 0.980 106.317 1.244
201809 0.410 106.507 0.519
201812 -0.070 105.998 -0.089
201903 -0.510 107.251 -0.642
201906 -0.180 108.070 -0.225
201909 0.830 108.329 1.034
201912 0.890 108.420 1.108
202003 -0.240 108.902 -0.297
202006 1.730 108.767 2.146
202009 0.730 109.815 0.897
202012 3.440 109.897 4.223
202103 1.280 111.754 1.545
202106 0.090 114.631 0.106
202109 -0.610 115.734 -0.711
202112 3.500 117.630 4.015
202203 -0.070 121.301 -0.078
202206 -1.130 125.017 -1.220
202209 -1.750 125.227 -1.886
202212 -1.760 125.222 -1.896
202303 -3.710 127.348 -3.931
202306 -5.160 128.729 -5.408
202309 -5.080 129.860 -5.278
202312 -0.950 129.419 -0.990
202403 0.170 131.776 0.174
202406 -5.380 132.554 -5.476
202409 2.060 133.029 2.089
202412 -0.580 133.157 -0.588
202503 1.190 134.927 1.190

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emergent BioSolutions  (NYSE:EBS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Emergent BioSolutions Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions Business Description

Traded in Other Exchanges
Address
300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Executives
Keith Katkin director C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Neal Franklin Fowler director C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Marvin L White director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
William Hartzel officer: SVP, Bioservices 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii officer: Interim CEO EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Paul Anthony Williams officer: SVP, Products Business 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal director C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Glessner Coleen officer: EVP, Quality & Ethics, and CPL 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox officer: EVP, Ext Aff, GC, Corp Sec 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl officer: EVP, Chief Financial Officer NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey officer: EVP, BioDefense Division 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853